# Evaluate the Efficacy and Safety of LivPhcD Capsules in the NAFLD Subjects

> **NCT05930093** · NA · RECRUITING · sponsor: **TCM Biotech International Corp.** · enrollment: 108 (estimated)

## Conditions studied

- NAFLD

## Interventions

- **DIETARY_SUPPLEMENT:** Placebo
- **DIETARY_SUPPLEMENT:** 2 cap.LivPhcD/per day
- **DIETARY_SUPPLEMENT:** 4 cap.LivPhcD/per day
- **DIETARY_SUPPLEMENT:** 6 cap.LivPhcD/per day

## Key facts

- **NCT ID:** NCT05930093
- **Lead sponsor:** TCM Biotech International Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-07
- **Primary completion:** 2026-01
- **Final completion:** 2026-05-01
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05930093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05930093, "Evaluate the Efficacy and Safety of LivPhcD Capsules in the NAFLD Subjects". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05930093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*